167 related articles for article (PubMed ID: 15932563)
41. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer.
Wang JY; Lu CY; Chu KS; Ma CJ; Wu DC; Tsai HL; Yu FJ; Hsieh JS
Eur Surg Res; 2007; 39(4):245-50. PubMed ID: 17457032
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9.
Weissenberger C; Von Plehn G; Otto F; Barke A; Momm F; Geissler M
Anticancer Res; 2005; 25(3A):1787-93. PubMed ID: 16033101
[TBL] [Abstract][Full Text] [Related]
43. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS
Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156
[TBL] [Abstract][Full Text] [Related]
44. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg Oncol; 2007 Feb; 14(2):493-9. PubMed ID: 17103067
[TBL] [Abstract][Full Text] [Related]
45. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
[TBL] [Abstract][Full Text] [Related]
46. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer.
Ishigami S; Sakamoto A; Uenosono Y; Nakajo A; Okumura H; Matsumoto M; Setoyama T; Arigami T; Uchikado Y; Arima H; Natsugoe S; Aikou T
J Surg Res; 2008 Aug; 148(2):205-9. PubMed ID: 17936797
[TBL] [Abstract][Full Text] [Related]
47. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: a prospective study.
Jess P; Iversen LH; Nielsen MB; Hansen F; Laurberg S; Rasmussen PC
Dis Colon Rectum; 2008 Jun; 51(6):868-74. PubMed ID: 18297361
[TBL] [Abstract][Full Text] [Related]
48. Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei.
Chua TC; Yan TD; Yap ZL; Horton MD; Fermanis GG; Morris DL
J Surg Oncol; 2009 Apr; 99(5):292-5. PubMed ID: 19180588
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous bicavitary hyperthermic chemoperfusion in the management of pseudomyxoma peritonei with synchronous pleural extension.
Senthil M; Harrison LE
Arch Surg; 2009 Oct; 144(10):970-2. PubMed ID: 19841367
[TBL] [Abstract][Full Text] [Related]
50. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
Pissaia A; Bernard D; Scatton O; Soubrane O; Conti F; Calmus Y
Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
[TBL] [Abstract][Full Text] [Related]
51. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
Park YA; Sohn SK; Seong J; Baik SH; Lee KY; Kim NK; Cho CW
J Surg Oncol; 2006 Feb; 93(2):145-50. PubMed ID: 16425302
[TBL] [Abstract][Full Text] [Related]
52. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis.
Körner H; Söreide K; Stokkeland PJ; Söreide JA
Ann Surg Oncol; 2007 Feb; 14(2):417-23. PubMed ID: 17103264
[TBL] [Abstract][Full Text] [Related]
54. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
55. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
56. A profile of tumor markers in the population of Kuwait.
al-Sayer H; al-Bader A; Hussein T; Mathew A; Behbehani A; Dashti H; Farghaly M; Khorsheed M; Van Dalen A
Anticancer Res; 1999; 19(3B):2369-72. PubMed ID: 10472358
[TBL] [Abstract][Full Text] [Related]
57. Pseudomyxoma peritonei.
Smeenk RM; Bruin SC; van Velthuysen ML; Verwaal VJ
Curr Probl Surg; 2008 Aug; 45(8):527-75. PubMed ID: 18590843
[No Abstract] [Full Text] [Related]
58. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study.
Oussoultzoglou E; Rosso E; Fuchshuber P; Stefanescu V; Diop B; Giraudo G; Pessaux P; Bachellier P; Jaeck D
Arch Surg; 2008 Dec; 143(12):1150-8; discussion 1158-9. PubMed ID: 19075165
[TBL] [Abstract][Full Text] [Related]
59. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
[TBL] [Abstract][Full Text] [Related]
60. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.
Nummela P; Leinonen H; Järvinen P; Thiel A; Järvinen H; Lepistö A; Ristimäki A
Hum Pathol; 2016 Aug; 54():47-54. PubMed ID: 27038681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
